首页> 外文期刊>Current opinion in lipidology >Hyperlipidaemia and cardiovascular disease: inflammation and oxidative stress in diabetic patients.
【24h】

Hyperlipidaemia and cardiovascular disease: inflammation and oxidative stress in diabetic patients.

机译:高脂血症和心血管疾病:糖尿病患者的炎症和氧化应激。

获取原文
获取原文并翻译 | 示例
           

摘要

The 'lipid infiltration' hypothesis of atherosclerosis is based on the classical investigation of Anitchkov and Chalatov who, about 100 years ago, induced experimental atherosclerosis in rabbits by cholesterol feeding. Today, we know that there are additional participants in atherosclerosis development that involve inflammation, diabetes (insulin resistance), endothelial injury, lipoproteins retention in the arterial wall, and lipoproteins modifications (lipids and protein hydrolysis, and oxidation). The serum inflammatory biomarker C reactive protein (GRP) predicts cardiovascular disease (CVD) events. Indeed, in the Japanese Coronary Artery Disease (JGAD) research performed on 15 628 patients with significant coronary stenosis, elevated serum level of CRP was clearly shown to be an independent predictor of cardiovascular events [1]. As it is not clear whether CRP predicts CVD independent of insulin resistance, a prospective population-based study was carried out on 2357 Danish men and women, free of major CVD at baseline. Both serum CRP and insulin resistance were found to be independently related to the risk of CVD [2]. The JUPITER trial showed in 17802 participants without hyperlipidemia, but with high serum CRP protein levels, that the statin rosuvastatin significantly decreased the incidence of major CVD events such as myocardial infarction, stroke, or death from cardiovascular causes [3].
机译:动脉粥样硬化的“脂质浸润”假说是基于对Anitchkov和Chalatov的经典研究得出的,Anitchkov和Chalatov大约在100年前通过胆固醇喂养诱导兔实验性动脉粥样硬化。今天,我们知道动脉粥样硬化发展中还有其他参与者,涉及炎症,糖尿病(胰岛素抵抗),内皮损伤,动脉壁中脂蛋白的保留和脂蛋白的修饰(脂质和蛋白水解以及氧化)。血清炎症生物标志物C反应蛋白(GRP)预测心血管疾病(CVD)事件。确实,在日本冠状动脉疾病(JGAD)中对15 628例具有明显冠状动脉狭窄的患者进行的研究中,血清CRP水平的升高清楚地表明是心血管事件的独立预测因素[1]。由于尚不清楚CRP是否可以预测CVD是否独立于胰岛素抵抗,因此对2357名丹麦男性和女性进行了一项基于人群的前瞻性研究,基线时无主要CVD。发现血清CRP和胰岛素抵抗均与CVD风险独立相关[2]。 JUPITER试验显示,在17802名没有高脂血症,但血清CRP蛋白水平高的参与者中,他汀类药物瑞舒伐他汀显着降低了主要CVD事件的发生率,例如心肌梗塞,中风或心血管原因导致的死亡[3]。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号